Vivani Medical, Inc. (VANI) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.22

From 52W high−36.36%

Volume904307.00

Market cap$107.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.22

From 52W high

−36.36%

Volume

904307.00

Market cap

$107.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.9x

P/E (TTM)

—

RSI (14)

35.6

MomentumView details →

1D Return

−1.65%

YTD Return

−4.07%

SummaryUpdated Jun 1, 2026

Vivani Medical, Inc. (NASDAQ:VANI) is a clinical-stage medical device company founded in 2014 and headquartered in Emeryville, California. The company went public in November 2014 and focuses on developing innovative implantable medical devices to address chronic diseases with significant unmet medical needs. Vivani operates as a pre-revenue company, dedicating its resources to advancing two primary technology platforms through clinical development stages.

Ask drillr about Vivani Medical, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−138.73%

ROA (TTM)

−63.19%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+22.22%

FCF YoY

−14.54%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+0.00%

EBITDA YoY

−6.19%

MomentumView details →

1D Return

−1.65%

YTD Return

−4.07%

1Y Return

−16.31%

RSI (14)

35.6

vs 50D SMA

−12.11%

vs 200D SMA

−7.02%

Capital & dividendView details →

Debt/Equity

0.94x

Current Ratio

3.25x

Quick Ratio

3.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.07

EPS Surprise

16.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.08

Avg Surprise (4Q)

6.08%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−26.31M

Op. CF (TTM)

−25.30M

Next earningsNov 12, 2026 →

Latest newsMore news →

Vivani Medical announced it is preparing to begin human testing of its semaglutide implant in August.67d ago

Novo Nordisk signed an agreement with Vivani Medical to evaluate Vivani's experimental NPM-139 implant for continuous semaglutide delivery.71d ago

Similar companies

electroCore, Inc.ECOR FONAR CorporationFONR MaxCyte, Inc.MXCT MicroPort CardioFlow Medtech Corporation02160.HK Apyx Medical CorporationAPYX Pulmonx CorporationLUNG Find similar companies →

Latest newsMore news →

Vivani Medical announced it is preparing to begin human testing of its semaglutide implant in August.67d ago Novo Nordisk signed an agreement with Vivani Medical to evaluate Vivani's experimental NPM-139 implant for continuous semaglutide delivery.71d ago Vivani Medical signed an agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, a semaglutide drug implant for chronic weight management.75d ago